June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Lung Show-Me-Tips
Coding...Abstracting...Education… Coding Systemic Therapy Lung Cancer Systemic Therapy
Non-Small Cell Lung Cancer Chemotherapy Subcategory Abraxane (Protein-bound Paclitaxel) Taxane
Afinitor (Everolimus) Cytostatic agent--antiangiogenesis agent and mTOR inhibitor
Alectinib (Alecensa) ALK Inhibitor
Brigatinib (Alunbrig) Anaplastic lymphoma kinase
Carboplatin (Paraplatin) Alkylating agent , Platinum analog
Ceritinib (Zykadia) ALK tyrosine kinase inhibitor
Crizotinib (Xalkori) Kinase inhibitor, Target- ed therapy anaplastic lymphoma kinase
Erlotinib (Tarceva, Erlotinib Hydrochloride) Cytostatic agent--tyrosine kinase inhibitor, EGF inhibitor
Docetaxel (Taxotere) Taxane
Gefitinib (Iressa) Cytostatic agent--tyrosine kinase inhibitor
Gilotrif (Afatinib) Tyrosine kinase inhibitor
Gemcitabine (Gemzar) Antimetabolite
Irinotecan (Camptosar) Topoisomerase inhibitor
Mechlorethamine (Mustargen, Nitrogen Mustard) Alkylating agent
Methotrexate (Folex, Mexate) Antimetabolite
Paclitaxel (Taxol) Mitotic inhibitor, plant alkaloid, Taxane
Pemetrexed (Alimta) Antimetabolite Tagrisso (Osimertinib) EGFR-TKI inhibitor
Vinorelbine (Navelbine) Plant alkyloid
Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR
This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 1
June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Lung Show-Me-Tips
Coding...Abstracting...Education… Coding Systemic Therapy Lung Cancer Systemic Therapy
Small Cell Lung Cancer Chemotherapy Only Subcategory Afinitor (Everolimus) Cytostatic agent--antiangiogenesis agent and mTOR inhibitor Doxorubicin (Adriamycin) Antitumor antibiotic Etoposide (Eposine, Etopophos) Epipodophyllotoxin, topoisomerase II inhibitor, Plant alkaloid Irinotecan (Camptosar) + Cisplatin or Carboplatin Topoisomerase inhibitor Mechlorethamine (Mustargen, Nitrogen Mustard) Alkylating agent Methotrexate (Folex, Mexate) Antimetabolite Topotecan (Hycamtin) Topoisomerase inhibitor
Biological Response Modifiers Subcategory
Atezolizumab* (Tecentriq, MPDL3208A) Monoclonal antibody
Bevacizumab (Avastin) Cytostatic agent--antiangiogenesis agent, Recombinant human anti-VEGF, Vascular endothelial growth factor receptor inhibitor
Cyramza (Ramucirumab) Antiangiogenesis, Monoclonal antibody
Durvalumab* (Imfinzi) FDA approved 2/18 None
Keytruda (Pembrolizumab) approved 10/18 Monoclonal antibody
Necitumumab (Portrazza) Anti-EFRG monoclonal antibody
Nivolumab* (Opdivo) braf inhibitor
* PD-L1 inhibitors: interacts with the Common drug combinations PD-1 protein on T cells Carboplatin & Taxol
Gemzar & Cisplatin
Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR
This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 2